Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Tax Provisions: 2021-2025

Historic Tax Provisions for Spyre Therapeutics (SYRE) over the last 3 years, with Mar 2025 value amounting to -$15,000.

  • Spyre Therapeutics' Tax Provisions fell 146.88% to -$15,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $36,000, marking a year-over-year increase of 500.00%. This contributed to the annual value of $51,000 for FY2024, which is 296.15% up from last year.
  • Spyre Therapeutics' Tax Provisions amounted to -$15,000 in Q1 2025, which was down 1,600.00% from $1,000 recorded in Q4 2024.
  • In the past 5 years, Spyre Therapeutics' Tax Provisions ranged from a high of $38,000 in Q4 2022 and a low of -$209,000 during Q3 2022.
  • Over the past 3 years, Spyre Therapeutics' median Tax Provisions value was $3,000 (recorded in 2023), while the average stood at $1,429.
  • In the last 5 years, Spyre Therapeutics' Tax Provisions plummeted by 903.85% in 2022 and then surged by 500.00% in 2024.
  • Spyre Therapeutics' Tax Provisions (Quarterly) stood at $23,000 in 2021, then skyrocketed by 65.22% to $38,000 in 2022, then spiked by 101.44% to $3,000 in 2023, then soared by 500.00% to $1,000 in 2024, then crashed by 146.88% to -$15,000 in 2025.
  • Its last three reported values are -$15,000 in Q1 2025, $1,000 for Q4 2024, and $18,000 during Q3 2024.